Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug991 | Communication Wiki | 1.00 |
| drug4113 | Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 Wiki | 1.00 |
| drug4114 | Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This study is a randomized, double-blinded clinical Trial, to evaluate the non-inferiority of the commercial scale Inactivated SARS-CoV-2 vaccine against that of the pilot scale among adults aged 26-45 years, and the open-labelled, bridging non-inferiority of the vaccine induced immunogenicity in elderly against that in adults.
Description: Neutralizing antibody assay will be performed using the micro-neutralization method
Measure: Immunogenicity index-geometric mean titer(GMT) of neutralizing antibody Time: Day 14 after the full course vaccinationDescription: Neutralizing antibody assay will be performed using the micro-neutralization method. Seroconversion will be defined as a change from seronegative(<1:8) to seropositive(≥1:8), or ≥4 fold increase from baseline
Measure: Immunogenicity index-Seroconversion rate of the neutralizing antibody Time: Day 14 after the full course vaccinationDescription: Neutralizing antibody assay will be performed using the micro-neutralization method. Subjects with a antibody titer ≥1:8 will defined as seropositive
Measure: Immunogenicity index-Seropositive rate of the neutralizing antibody Time: Day 14 after the full course vaccinationDescription: Incidence of adverse reactions from the beginning of the vaccination to 28 days after the full course vaccination
Measure: Safety index-Incidence of adverse reactions Time: From the beginning of the vaccination to 28 days after the full course vaccinationDescription: SAE will be collected throughout the clinical trial
Measure: Safety index-Incidence of serious adverse events Time: From the beginning of the vaccination to 6 months after the full course vaccinationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports